Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease.

C H Hennekens1

  • 1Mount Sinai Medical Center-Miami Heart Institute and Department of Medicine, Epidemiology, and Public Health, University of Miami School of Medicine, Miami Beach, Florida 33140, USA. PROFCHHMD@prodigy.net

Clinical Cardiology
|July 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.

Journal of the American College of Cardiology·2001
Same author

Relations of body fat distribution and height with cataract in men.

The American journal of clinical nutrition·2000
Same author

Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men.

Hypertension (Dallas, Tex. : 1979)·2000
Same author

An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.

Archives of internal medicine·2000
Same author

Clinical and research challenges in risk factors for cardiovascular diseases.

European heart journal·2000
Same author

Triggering of sudden death from cardiac causes by vigorous exertion.

The New England journal of medicine·2000
Same journal

In-Hospital Cardiac Arrest Detection Performance Analysis and Comparison on Effective Feature Selection.

Clinical cardiology·2026
Same journal

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy.

Clinical cardiology·2026
Same journal

Heart Failure With Preserved Ejection Fraction-Like Phenotype in Coronary Artery Disease and Obstructive Sleep Apnea: Insights From the RICCADSA Cohort.

Clinical cardiology·2026
Same journal

Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.

Clinical cardiology·2026
Same journal

Methodological Considerations Regarding Diuretic Intensity Score and Mortality in Hospitalized Heart Failure Patients.

Clinical cardiology·2026
Same journal

Inpatient Outcomes and Complications After Left Atrial Appendage Occlusion in Rural Versus Urban Hospitals in the United States.

Clinical cardiology·2026
See all related articles

Managing global cardiovascular disease (CVD) risk, particularly elevated lipid levels, is crucial. Statins effectively reduce CVD events, yet many at-risk patients remain undertreated or not at treatment goals.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) poses a significant health burden.
  • Management of individual risk factors is important, but global risk assessment is optimal.
  • Elevated lipid levels are a major contributor to overall CVD risk.

Purpose of the Study:

  • To emphasize the importance of managing global CVD risk.
  • To highlight the role of lipid reduction in mitigating CVD.
  • To discuss the benefits and current underutilization of statins.

Main Methods:

  • Review of clinical guidelines and evidence regarding CVD risk management.
  • Focus on the role of lipid-lowering therapies, specifically statins.
  • Analysis of patient treatment status relative to established goals.

Related Experiment Videos

Main Results:

  • Elevated lipid values significantly contribute to global CVD risk.
  • Statins (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) demonstrate clear clinical benefits in reducing myocardial infarction, stroke, and mortality.
  • A significant gap exists between the known benefits of statins and their actual use, with many at-risk patients undertreated or not achieving lipid goals.

Conclusions:

  • Comprehensive management of global CVD risk is essential for effective patient care.
  • Lipid reduction, particularly through statin therapy, is a cornerstone of CVD prevention.
  • Addressing the undertreatment and suboptimal goal attainment of statin therapy is critical to improve patient outcomes and reduce the incidence of cardiovascular events.